S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CLGN

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

$5.39
+0.16 (+3.06%)
(As of 03/28/2024 ET)
Today's Range
$5.25
$5.47
50-Day Range
$4.71
$5.80
52-Week Range
$4.22
$8.90
Volume
2,648 shs
Average Volume
9,068 shs
Market Capitalization
$61.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

CollPlant Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.1% Upside
$11.00 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of CollPlant Biotechnologies in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.11 to ($0.57) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

682nd out of 938 stocks

Biotechnology Industry

30th out of 47 stocks

CLGN stock logo

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CLGN Stock Price History

CLGN Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
CollPlant Issues Letter to Shareholders
CollPlant Issues Letter to Shareholders
COLLPLANT BIOTECH. IS-,01 (CPT.MU)
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Recap: CollPlant Biotechnologies Q3 Earnings
Collplant Holdings (CLGN) Gets a Buy from H.C. Wainwright
See More Headlines
Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/24/2023
Today
3/29/2024
Next Earnings (Confirmed)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:CLGN
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+104.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,920,000.00
Pretax Margin
-62.80%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$2.91 per share

Miscellaneous

Free Float
10,354,000
Market Cap
$61.72 million
Optionable
Optionable
Beta
0.25
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Yehiel Tal (Age 72)
    CEO & Director
    Comp: $865k
  • Mr. Eran Rotem CPA (Age 56)
    Deputy CEO & CFO
    Comp: $651k
  • Prof. Oded Shoseyov (Age 68)
    Founder & Chief Scientist
    Comp: $384k
  • Mr. Oren Fahimipoor (Age 42)
    Vice President of Operations
  • Ms. Hadas Dreiher Horowitz (Age 47)
    Vice President of Human Resources
  • Dr. Elana Gazal (Age 49)
    Vice President of Research & Development

CLGN Stock Analysis - Frequently Asked Questions

Should I buy or sell CollPlant Biotechnologies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLGN shares.
View CLGN analyst ratings
or view top-rated stocks.

What is CollPlant Biotechnologies' stock price target for 2024?

1 brokerages have issued 12-month target prices for CollPlant Biotechnologies' shares. Their CLGN share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for CLGN
or view top-rated stocks among Wall Street analysts.

How have CLGN shares performed in 2024?

CollPlant Biotechnologies' stock was trading at $6.39 at the beginning of 2024. Since then, CLGN shares have decreased by 15.6% and is now trading at $5.39.
View the best growth stocks for 2024 here
.

Are investors shorting CollPlant Biotechnologies?

CollPlant Biotechnologies saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 8,100 shares, a decline of 13.8% from the February 29th total of 9,400 shares. Based on an average trading volume of 11,400 shares, the short-interest ratio is currently 0.7 days. Approximately 0.1% of the company's shares are sold short.
View CollPlant Biotechnologies' Short Interest
.

When is CollPlant Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CLGN earnings forecast
.

How can I listen to CollPlant Biotechnologies' earnings call?

CollPlant Biotechnologies will be holding an earnings conference call on Thursday, April 4th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) announced its quarterly earnings data on Thursday, August, 24th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.83. The firm had revenue of $10.18 million for the quarter, compared to the consensus estimate of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 20.61% and a negative net margin of 62.80%. During the same quarter last year, the company earned ($0.39) EPS.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and

When did CollPlant Biotechnologies IPO?

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (4.22%), Roumell Asset Management LLC (3.90%), Villere ST Denis J & Co. LLC (3.26%), Benjamin F. Edwards & Company Inc. (0.45%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLGN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners